The Online Investor
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Fri., Dec. 6, 8:55 PM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #9. Boston Scientific IoGyn, Inc.

Acquirer: Boston Scientific (NYSE:BSX)
Acquiree: IoGyn, Inc.
Details: Boston Scientific Corporation (NYSE: BSX) has signed a definitive agreement to acquire IoGyn, Inc., a pre-commercial stage company. The transaction is expected to close within days. IoGyn has developed and received U.S. Food and Drug Administration (FDA) clearance for the Symphion System, a next generation system for hysteroscopic intrauterine tissue removal including fibroids (myomas) and polyps. This acquisition enables the pairing of the Symphion System with the Boston Scientific Genesys HTA System for abnormal uterine bleeding, to create a compelling set of gynecologic surgery products.

Boston Scientific is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical fields. Co.'s businesses include: Endoscopy, which develops and manufactures devices to diagnose and treat gastrointestinal and pulmonary conditions; Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions; Cardiac Rhythm Management, which develops and manufactures implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; and Neuromodulation, which develops and manufactures devices to treat various neurological movement disorders and manage chronic pain.

Boston Scientific SEC Filing Email Alerts Service


Open the BSX Page at The Online Investor »

Company Name: 
Boston Scientific Corp.
Website: 
www.bostonscientific.com
Sector: 
Medical Instruments & Supplies
Number of ETFs Holding BSX: 
75
Total Market Value Held by ETFs: 
$5.06B
Total Market Capitalization: 
$59.95B
% of Market Cap. Held by ETFs: 
8.45%
 

Open the BSX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (3.86 out of 4)
76th percentile
(ranked higher than approx. 76% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Healthcare M&A - Slide 9 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.